Naringenin attenuates the release of pro-inflammatory mediators from lipopolysaccharide-stimulated BV2 microglia by inactivating nuclear factor-κB and inhibiting mitogen-activated protein kinases

International Journal of Molecular Medicine

Volumn 30, Issue 1, 2012, Pages 204-210

  Park, Hye Young ^a,b   Kim, Gi Young ^c   Choi, Yung Hyun ^a,d  

^a Dong Eui University   (South Korea)

^b Pusan National University   (South Korea)

^c Jeju National University   (South Korea)

^d Dong Eui University   (South Korea)

Author keywords

Akt; Anti inflammation; Mitogen activated protein kinase; Naringenin; Nuclear factor B

Indexed keywords

CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NARINGENIN; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL NUCLEUS; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOKINE CCL2; CYCLOOXYGENASE 2; DINOPROSTONE; FLAVANONES; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861468754     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.979     Document Type: Article

References (45)

1. Gebicke-Haerter PJ: Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 54: 47-58, 2001.
2. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C and Gendelman HE: Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin Neurosci Res 6: 261-281, 2006. (Pubitemid 44849177)
3. Reynolds A, Laurie C, Mosley RL and Gendelman HE: Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 82: 297-325, 2007.
4. Perry VH, Nicoll JA and Holmes C: Microglia in neurodegenerative disease. Nat Rev Neurol 6: 193-201, 2010.
5. Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immun 17: 13-19, 2003.
6. Das S and Basu A: Inflammation: a new candidate in modulating adult neurogenesis. J Neurosci Res 86: 199-1208, 2008.
7. Long-Smith CM, Sullivan AM and Nolan YM: The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 89: 277-287, 2009.
8. Lull ME and Block ML: Microglial activation and chronic neurodegeneration. Neurotherapeutics 7: 354-365, 2010.
9. Stadelmann C: Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol 24: 224-229, 2011.
10. Dixon RA and Steele CL: Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci 4: 394-400, 1999.
11. Chen D, Chen MS, Cui QC, Yang H and Dou QP: Structure-proteasome- inhibitory activity relationships of dietary flavonoids in human cancer cells. Front Biosci12: 1935-1945, 2007. (Pubitemid 46846817)
12. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR and Kolonel LN: Intake of flavonoids and lung cancer. J Natl Cancer Inst 92: 154-160, 2000. (Pubitemid 30089873)
13. Szejtli J and Szente L: Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur J Pharm Biopharm 61: 115-125, 2005. (Pubitemid 41427619)
14. Rouseff RL: Liquid chromatographic determination of naringin and neohesperidin as a detector of grapefruit juice in orange juice. J Assoc Off Anal Chem 71: 798-802, 1988.
15. Hare JT and Elliott DP: Grapefruit juice and potential drug interactions. Consult Pharm 18: 466-472, 2003. (Pubitemid 38186006)
16. Ruh MF, Zacharewski T, Connor K, Howell J, Chen I and Safe S: Naringenin: a weakly estrogenic bioflavonoid that exhibits antiestrogenic activity. Biochem Pharmacol 50: 1485-1493, 1995.
17. Knowles LM, Zigrossi DA, Tauber RA, Hightower C and Milner JA: Flavonoids suppress androgen-independent human prostate tumor proliferation. Nut Cancer 38: 116-122, 2000. (Pubitemid 32377951)
18. Galati G, Moridani MY, Chan TS and O'Brien PJ: Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: glutathione oxidation and conjugation. Free Radic Biol Med 30: 370-382, 2001. (Pubitemid 32155536)
19. van Meeuwen JA, Korthagen N, de Jong PC, Piersma AH and van den Berg M: (Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture. Toxicol Appl Pharmacol 221: 372-383, 2007. (Pubitemid 46855806)
20. Galluzzo P, Ascenzi P, Bulzomi P and Marino M: The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptor α-palmitoylation. Endocrinology 149: 2567-2575, 2008. (Pubitemid 351577394)
21. Chen YC, Shen SC and Lin HY: Rutinoside at C7 attenuates the apoptosis-inducing activity of flavonoids. Biochem Pharmacol 66: 1139-1150, 2003.
22. Kanno S, Tomizawa A, Hiura T, Osanai Y, Shouji A, Ujibe M, Ohtake T, Kimura K and Ishikawa M: Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull 28: 527-530, 2005. (Pubitemid 40879982)
23. Kanno S, Tomizawa A, Ohtake T, Koiwai K, Ujibe M and Ishikawa M: Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells. Toxicol Lett 166: 131-139, 2006. (Pubitemid 44291963)
24. Park JH, Jin CY, Lee BK, Kim GY, Choi YH and Jeong YK: Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells. Food Chem Toxicol 46: 3684-3690, 2008.
25. Wang BD, Yang ZY, Wang Q, Cai TK and Crewdson P: Synthesis, characterization, cytotoxic activities, and DNA-binding properties of the La(III) complex with Naringenin Schiff-base. Bioorg Med Chem 14: 1880-1888, 2006. (Pubitemid 43199520)
26. Divsalar A, Saboury AA, Ahadi L, Zemanatiyar E and Mansouri-Torshizi H: Investigation of effects of newly synthesized Pt(II) complex against human serum albumin and leukemia cell line of K562. BMB Rep 43: 766-771, 2010.
27. Woo A, Min B and Ryoo S: Piceatannol-3′-O-beta-D-glucopyranoside as an active component of rhubarb activates endothelial nitric oxide synthase through inhibition of arginase activity. Exp Mol Med 42: 524-532, 2010.
28. Choi JH, Park JG, Jeon HJ, Kim MS, Lee MR, Lee MN, Sonn S, Kim JH, Lee MH, Choi MS, et al: 5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion. Exp Mol Med 43: 471-478, 2011.
29. Jin CY, Moon DO, Lee KJ, Kim MO, Lee JD, Choi YH, Park YM and Kim GY: Piceatannol attenuates lipopolysaccharide-induced NF-kappaB activation and NF-kappaB-related proinflammatory mediators in BV2 microglia. Pharmacol Res 54: 461-467, 2006. (Pubitemid 46075095)
30. Garden GA and Möller T: Microglia biology in health and disease. J Neuroimmune Pharmacol 1: 127-137, 2006. (Pubitemid 44257488)
31. Sugama S, Takenouchi T, Fujita M, Conti B and Hashimoto M: Differential microglial activation between acute stress and lipopolysaccharide treatment. J Neuroimmunol 207: 24-31, 2009.
32. Schwartz M and Shechter R: Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 6: 405-410, 2010.
33. Wright JG and Christman JW: The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2: 211-219, 2003. (Pubitemid 36869436)
34. Atreya I, Atreya R and Neurath MF: NF-kappaB in inflammatory bowel disease. J Int Med 263: 591-596, 2008.
35. Sebban H and Courtois G: NF-kappaB and inflammation in genetic disease. Biochem Pharmacol 72: 1153-1160, 2006.
36. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr and Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 20: 1626-1638, 2000. (Pubitemid 30100182)
37. Lee JY, Jhun BS, Oh YT, Lee JH, Choe W, Baik HH, Ha J, Yoon KS, Kim SS and Kang I: Activation of adenosine A3 receptor suppresses lipopolysaccharide- induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett 396: 1-6, 2006. (Pubitemid 43233777)
38. Shin WS, Szuba A and Rockson SG: The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160: 91-102, 2002. (Pubitemid 34076646)
39. Nam NH: Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6: 945-951, 2006.
40. Luqman S and Pezzuto JM. NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res 24: 949-963, 2010.
41. Kim SH, Smith CJ and Van Eldik LJ: Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging 25: 431-439, 2004. (Pubitemid 38317340)
42. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A and Lipko M: MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec 292: 1902-1913, 2009.
43. Kaminska B: MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754: 253-262, 2005.
44. Wei J and Feng J: Signaling pathways associated with inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov 4: 105-117, 2010.
45. Pyo H, Jou I, Jung S, Hong S and Joe EH: Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport 9: 871-874, 1998. (Pubitemid 28179292)